Phase 1 Study of a Long-acting Injectable S-892216 in Healthy Adult Participants

Shionogi

Summary

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.

Eligibility

Age range: 18–55 years
Sex: Male
Healthy volunteers: Yes

Detailed criteria

Key Inclusion Criteria: * Body mass index (BMI) ≥18.5 and ≤32.0 kilograms (kg)/square meter (m\^2) Key Exclusion Criteria: * Presence or history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, neurological, or ophthalmological (for example, increased intra-ocular pressure) disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data per the investigator's assessment. * History of cancer except for basal…

Interventions

Drug
S-892216-LAI
S-892216-LAI injection will be administered per schedule specified in the arm description.
Drug
Placebo
Physiological saline will be administered per schedule specified in the arm description.

Locations (2)

ICON Clinical Research: Lenexa
Lenexa, Kansas
ICON Clinical Research: Salt Lake City
Salt Lake City, Utah

Phase 1 Study of a Long-acting Injectable S-892216 in Healthy Adult Participants

Summary

Eligibility

Interventions

Locations (2)

Compensation

Run this study?

Details

Conditions